Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Argent Biopharma ( (AU:RGT) ).
Argent BioPharma announced promising results from an independent in vivo study conducted by the University of South Florida, which demonstrated the efficacy of ArtemiC™ in treating Acute Respiratory Distress Syndrome (ARDS) in a viral inflammatory model. The study, funded by AMC Pharma USA, showed significant improvements in survival rates and reductions in viral load and inflammation, supporting ArtemiC™’s potential as a non-immunosuppressive treatment for ARDS and related conditions. These findings bolster Argent BioPharma’s strategy for expanding the availability of ArtemiC™ in the U.S. and other markets, potentially offering a new therapeutic option for managing severe infections and inflammatory diseases.
More about Argent Biopharma
Argent BioPharma Ltd. (ASX: RGT) is a clinical-stage biopharmaceutical company specializing in nano-engineered medicines aimed at restoring balance between the nervous and immune systems. The company focuses on developing treatments for drug-resistant epilepsy and cytokine-driven inflammatory and autoimmune disorders, with its lead candidates being CannEpil® and CimetrA®. Argent BioPharma employs proprietary delivery platforms to enhance drug efficacy and is committed to addressing urgent unmet needs in CNS and systemic inflammation.
YTD Price Performance: -23.53%
Average Trading Volume: 85,906
Technical Sentiment Signal: Sell
Current Market Cap: A$8.03M
See more data about RGT stock on TipRanks’ Stock Analysis page.